{"id":55606,"date":"2026-01-27T17:42:15","date_gmt":"2026-01-27T09:42:15","guid":{"rendered":"https:\/\/flcube.com\/?p=55606"},"modified":"2026-01-27T17:42:16","modified_gmt":"2026-01-27T09:42:16","slug":"nuance-pharma-secures-nmpa-review-for-ensifentrine-copd-maintenance-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55606","title":{"rendered":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy"},"content":{"rendered":"\n<p><strong>Nuance Pharma<\/strong> announced that its market filing for <strong>Ohtuvayre (ensifentrine)<\/strong> as maintenance treatment for patients with <strong>Chronic Obstructive Pulmonary Disease (COPD)<\/strong> has been accepted for review by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status-amp-product-profile\">Regulatory Status &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Nuance Pharma<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ohtuvayre (ensifentrine)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>First\u2011in\u2011class phosphodiesterase 3 and 4 (PDE3\/PDE4) inhibitor<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Maintenance treatment of COPD in adults<\/td><\/tr><tr><td><strong>Delivery<\/strong><\/td><td>Inhaled via standard nebulizer<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>NMPA filing accepted for review<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Dual bronchodilatory and anti\u2011inflammatory effects in a single compound<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>First inhaled maintenance therapy for COPD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-innovation-amp-clinical-advantage\">Drug Innovation &amp; Clinical Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Inhibition:<\/strong> Simultaneous PDE3 and PDE4 blockade delivers both <strong>bronchodilation<\/strong> and <strong>anti\u2011inflammatory<\/strong> effects via a single active ingredient<\/li>\n\n\n\n<li><strong>Delivery Innovation:<\/strong> Administered via <strong>standard nebulizer<\/strong>, making it the <strong>first inhaled maintenance therapy<\/strong> for COPD, offering convenient outpatient and home\u2011based treatment<\/li>\n\n\n\n<li><strong>Clinical Value:<\/strong> Addresses both airway obstruction and underlying inflammation, key drivers of COPD progression and exacerbations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-amp-market-access-pathway\">Licensing &amp; Market Access Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Greater China Rights:<\/strong> Secured via licensing deal with <strong>UK\u2011based Verona Pharma plc<\/strong> in <strong>2021<\/strong><\/li>\n\n\n\n<li><strong>Corporate Update:<\/strong> Verona Pharma was acquired by <strong>Merck &amp; Co., Inc. (NYSE:\u202fMRK)<\/strong> in <strong>October\u202f2025<\/strong><\/li>\n\n\n\n<li><strong>Regional Access:<\/strong> Approved in <strong>Macau (February\u202f2025)<\/strong>; became available in the <strong>Greater Bay Area (November\u202f2025)<\/strong> via \u201cHong Kong Macau Drug and Device Access\u201d policy<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Establishes Nuance as the exclusive provider of the only dual\u2011PDE inhibitor for COPD maintenance in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China COPD Burden:<\/strong> Approximately <strong>100\u202fmillion<\/strong> COPD patients, with <strong>20\u201330%<\/strong> requiring maintenance therapy<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> COPD maintenance market valued at <strong>\u00a515\u201320\u202fbillion<\/strong> (~US$2.1\u20132.8\u202fbillion) annually, growing at <strong>8% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First inhaled maintenance therapy offers <strong>differentiated delivery<\/strong> vs. oral PDE4 inhibitors and LAMA\/LABA combinations<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Expected pricing at <strong>\u00a515,000\u201320,000<\/strong> per patient annually; NRDL inclusion discussions anticipated for <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project <strong>\u00a5800\u202fmillion\u20131.2\u202fbillion<\/strong> (US$110\u2013170\u202fmillion) peak annual sales by 2029, assuming 5% penetration of eligible COPD patients<\/li>\n\n\n\n<li><strong>Launch Timeline:<\/strong> NMPA review typically <strong>12\u201318 months<\/strong>; potential approval <strong>Q2\u2013Q3\u202f2027<\/strong> if no major queries<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NMPA review timeline, commercial expectations, and revenue projections for ensifentrine in China. Actual results may differ due to regulatory review outcomes, competitive dynamics, and market adoption rates for inhaled therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55608,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,230],"class_list":["post-55606","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-nuance-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55606\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy\" \/>\n<meta property=\"og:description\" content=\"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55606\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T09:42:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T09:42:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy\",\"datePublished\":\"2026-01-27T09:42:15+00:00\",\"dateModified\":\"2026-01-27T09:42:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2706.webp\",\"keywords\":[\"Market approval filings\",\"Nuance Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55606#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55606\",\"name\":\"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2706.webp\",\"datePublished\":\"2026-01-27T09:42:15+00:00\",\"dateModified\":\"2026-01-27T09:42:16+00:00\",\"description\":\"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55606\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55606#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55606","og_locale":"en_US","og_type":"article","og_title":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy","og_description":"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).","og_url":"https:\/\/flcube.com\/?p=55606","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T09:42:15+00:00","article_modified_time":"2026-01-27T09:42:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55606#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55606"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy","datePublished":"2026-01-27T09:42:15+00:00","dateModified":"2026-01-27T09:42:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55606"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55606#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","keywords":["Market approval filings","Nuance Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55606#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55606","url":"https:\/\/flcube.com\/?p=55606","name":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55606#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55606#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","datePublished":"2026-01-27T09:42:15+00:00","dateModified":"2026-01-27T09:42:16+00:00","description":"Nuance Pharma announced that its market filing for Ohtuvayre (ensifentrine) as maintenance treatment for patients with Chronic Obstructive Pulmonary Disease (COPD) has been accepted for review by China\u2019s National Medical Products Administration (NMPA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55606#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55606"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55606#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","width":1080,"height":608,"caption":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55606#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55606"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55606\/revisions"}],"predecessor-version":[{"id":55609,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55606\/revisions\/55609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55608"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}